Ensifentrine is under clinical development by Verona Pharma and currently in Phase II for Bronchiectasis. According to GlobalData, Phase II drugs for Bronchiectasis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ensifentrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ensifentrine overview
Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Ensifentrine (RPL-554) is under development for the treatment of allergic asthma, mild to moderate chronic asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, non cystic fibrosis bronchiectasis. The drug candidate is administered through inhalation route as a suspension. RPL-554 acts by targeting both phosphodiesterase 3 and phosphodiesterase 4 enzymes. It was also under development for the treatment of allergic rhinitis, idiopathic pulmonary fibrosis.
Ensifentrine (RPL-554) was under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Verona Pharma overview
Verona Pharma is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs. The company’s lead product candidate, ensifentrine, is a first-in-class, inhaled dual inhibitor targeting phosphodiesterase 3 and 4 (PDE3 and PDE4). Verona Pharma is focusing on ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also developing a fixed-dose combination of ensifentrine and glycopyrrolate, a long-acting muscarinic antagonist (LAMA), for nebulized delivery in COPD treatment. Additionally, the company is evaluating ensifentrine for the treatment of non-cystic fibrosis bronchiectasis (NCFBE), cystic fibrosis and asthma. Verona Pharma is headquartered in London, the UK.
For a complete picture of Ensifentrine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
